CVS Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 25.21.
CVS Group's Days Inventory for the
six
months ended in Dec. 2025 was 27.46.
CVS Group's Days Payable for the
six
months ended in Dec. 2025 was 40.55.
Therefore, CVS Group's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 12.12.
CVS Group (OTCPK:CVSGF) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
CVS Group Cash Conversion Cycle Related Terms
CVS Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for CVS Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVSGF vs HCA, THC, DVA: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, CVS Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVS Group Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CVS Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where CVS Group's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
CVS Group's Cash Conversion Cycle for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Group (CVSGF) has a Cash Conversion Cycle of 12.12 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CVS Group and its competitors.
Is CVS Group's Cash Conversion Cycle too high?
CVS Group's current Cash Conversion Cycle is 12.12. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.21. CVS Group's value of 12.12 is 33.4% below this industry median. Overall, CVS Group has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CVS Group's Cash Conversion Cycle compare to HCA and THC?
CVS Group's Cash Conversion Cycle of 12.12 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.21. CVS Group's value of 12.12 is 33.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CVS Group's current Cash Conversion Cycle of 12.12 is 33.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CVS Group and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CVS Group's current Cash Conversion Cycle is 12.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVS Group stock overvalued right now?
Based on GuruFocus' analysis, CVS Group (CVSGF) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.82, compared to a current price of $16.55 — trading 12.1% below its estimated fair value. The current Cash Conversion Cycle is 12.12 and 33.4% below the Healthcare Providers & Services industry median of 18.21. CVS Group's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For CVS Group (CVSGF), the current Cash Conversion Cycle is 12.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CVS Group (CVSGF) Overvalued in 2026?
Based on GuruFocus' analysis, CVS Group stock appears to be undervalued.
The current stock price of $16.55 is trading 12.1% below its estimated GF Value™ of $18.82.
GuruFocus considers CVS Group to be Modestly Undervalued.
Key valuation signals for CVSGF:
Cash Conversion Cycle: 12.12
GF Value™: $18.82 vs. price of $16.55 (12.1% below fair value)
Industry Position: 33.4% below the Healthcare Providers & Services median
No single metric tells the full story. See the CVSGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CVS Group PLC is a veterinary service provider in the United Kingdom. The group operates through three business divisions: Veterinary Practices, Laboratories, Crematoria, and Online Retail Business. The veterinary practice segment generates the majority of the revenues. The company facilitates its veterinary services through its diagnostics, laboratory reports, and pet cremation services. It also offers retail pharmacy through Animed Direct. Geographically, it generates the majority of its revenue from the United Kingdom and also operates in Australia.
90GF Score
Get the complete analysis for CVSGF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVSGF has been successfully added to your 
